ClinicalTrials.gg
RecruitingNCT06445114Updated Aug 5, 2026

Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer

A Phase 2 interventional study of Cisplatin in Oropharyngeal Cancer and Carcinoma, sponsored by Zachary Zumsteg. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Zachary Zumsteg · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing cisplatin in Oropharyngeal Neoplasms — 9 open to participants now, 18 under way, 5 of them phase 3. Cisplatin · Oropharyngeal Neoplasms.

Planned enrollment
15th of 26
50 · median 107
Started
2025
with 1 other
Phase 2
17 of 26
8 open now
Primary completion
2032-06
later than 17 of 17 live
Registered
25th of 26
by date

Among the 26 studies testing cisplatin in Oropharyngeal Neoplasms, this one is the 15th largest by planned enrollment, is one of 2 that started in 2025, is one of 17 in phase 2, reaches primary completion later than 17 of the 17 other live ones, and was the 25th registered.

Oropharyngeal Neoplasms

370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.

Browse Oropharyngeal Neoplasms studies →

Open to participants now

9 of the 26 studies testing cisplatin in Oropharyngeal Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 89 Oropharyngeal Neoplasms studies recruiting now, 76 (85%) set no upper age limit and 5 (6%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing cisplatin in Oropharyngeal Neoplasms, or all of them as a file.
02

Study summary

This is a single institution phase II study that will enroll patients with T0-3N0-2 p16-positive oropharyngeal squamous cell carcinoma (OSCC) undergoing resection of all gross visible disease at the primary site and in the lymph nodes.

Read the detailed description

All eligible patients will be treated with a de-intensified cisplatin-based chemoradiation regimen after undergoing transoral robotic surgery. Enrolled patients will be risk-assessed and assigned to specific regimens based on a combination of their post-operative cTTMV-HPV DNA, as determined by results from NavDx kits by Naveris, and pathologic features. All patients will receive a dose of 40 mg/m2 IV weekly concurrently with radiation therapy. Patients ineligible to receive cisplatin at this dose will undergo modified sydtemic therapy. Patients will recieve concurrent radiation in a dose of 30 Gy in 15 fractions to the primary tumor bed, ipsilateral neck +/- contralateral neck. Based on risk-stratification, some patients will receive a sequential boost of 10 Gy over 5 fractions or 20 Gy over 10 fractions.

03

Conditions studied

  • Oropharyngeal Cancer
  • Carcinoma

Keywords

  • Transoral Robotic Surgery (TORS)
  • pT0 tumors (unknown primary)
  • p16
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • AJCC 8th edition T0-3N0-2 p16-positive oropharyngeal (tonsil, base of tongue, glossotonsillar sulcus, soft palate, oropharyngeal wall) squamous cell carcinoma or squamous cell carcinoma of unknown primary involving the cervical lymph nodes. Cytologic diagnosis from a cervical lymph node is sufficient for diagnosis in the presence of clinical evidence of a primary tumor in the oropharynx.
  • For patients with pT0 tumors (unknown primary), there must be at least one lymph node present in cervical level II.
  • p16 is strongly positive by immunohistochemistry or high-risk HPV is detected by in-situ hybridization.
  • Have undergone or will undergo gross total resection of all known disease in the head and neck via transoral robotic surgery. For patients with clinical unknown primary tumors, a patient must undergo both ipsilateral tonsillectomy and base of tongue resection unless the primary is identified clinically or pathologically at the time of surgery. If the primary is identified, then only resection of the primary site is required. If the primary tumor is resected with negative margins with a non-robotic surgery, such as a diagnostic tonsillectomy, this is considered acceptable and further robotic surgery is not necessary.
  • Have undergone or will undergo neck dissection.
  • Have at least one of the following after surgery:

    • Pathologic stage T3
    • 2 or more positive lymph nodes
    • At least one lymph node >3cm
    • Contralateral lymph node involvement
    • Lymphovascular invasion
    • Perineural invasion
    • Extranodal extension
    • Close/positive margins: Close margins are considered ≤3mm from the peripheral margins and ≤1mm from the deep margin on the en bloc specimen, unless the area of close margin is re-resected and without carcinoma.
  • Patients consented preoperatively are required to have detectable cTTMV-HPV DNA based on pre-operative NavDx testing. For patients consented post-operatively, NavDx testing should be performed on the tumor tissue to ensure detectable HPV DNA and for HPV subtyping.
  • Age ≥ 18 years old
  • performance status 0 or 2 within 56 days of start of chemoradiation.
  • Women of require a negative serum or urine pregnancy test within 28 days prior to start of chemoradiation.
  • Written obtained from subject and ability for subject to comply with the requirements of the study.
  • Adequate hematologic and renal function within 56 days of start of chemoradiation, defined as:

    • ≥ 9.0 g/dL
    • ≥ 100, 000 cells/mm3
    • ≥ 1.5 X 109/L
    • Total ≤ 1.5 x (ULN)
    • /alanine aminotransferase ≤ 3.0 x upper limit of normal (ULN)
    • Serum creatinine ≤1.5 x upper limit of normal (ULN) OR a calculated ≥50 mL/min estimated using the following Cockcroft-Gault equation

Exclusion criteria

Exclusion Criteria:

  • AJCC 8th edition pT4 or cN3 disease.
  • Radiologic or clinical evidence of distant .
  • Recurrent disease.
  • Inability to achieve gross total resection at time of surgery.
  • Greater than 56 days (8 weeks) after surgical resection of the primary site.
  • Prior radiation to the head and neck > 30 Gy.
  • Prior active invasive (not in situ) within the prior 2 years, excluding cutaneous basal cell or squamous cell carcinoma, low or intermediate risk prostate cancer, papillary thyroid cancer, stage T1aN0 kidney cancer, low-grade T1-2N0 salivary cancer, AJCC 8th edition stage I-II breast cancer, well-differentiated neuroendocrine tumors (e.g., carcinoid tumors), low grade non-Hodgkin lymphoma, or Stage 0, I, and III cutaneous melanomas. Patients with synchronous or multifocal oropharyngeal cancers are not excluded, as long as at least one of these tumors meet inclusion criteria for the trial.
  • Severe, active co-morbidity, defined as follows:

    • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
    • Transmural myocardial infarction within the last 6 months
    • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of enrollment
    • Hepatic insufficiency resulting in clinical jaundice and/or known coagulation defects
  • Moderate to severe hearing loss.
  • Active connective tissue disease (e.g. systemic lupus erythematous, scleroderma) requiring .
  • Pregnant or breast-feeding women.
  • Prior allergic reaction to cisplatin.
  • within 30 days prior to the first dose of chemoradiation. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, BCG, and typhoid (oral vaccine). Season influenza vaccines for injection are generally killed virus vaccines and are allowed; however intranasal influenza vaccines (e.g. Flu-Mist®) are live attenuated vaccines and are not allowed.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Single Arm

    Low risk pathology with post-op HPV DNA (-): cisplatin-based chemoradiation with 30 Gy in 15 fractions and 3 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, and 15 of radiation. Low risk pathology with post-op HPV DNA (+): cisplatin-based chemoradiation with 40 Gy in 20 fractions and 4 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, and 22 of radiation. High risk pathology with post-op HPV DNA (-), excluding patients with both 5 LN+ and ENE+ or pre-op HPV DNA≤12 copies/mL: cisplatin-based radiation with 40 Gy in 20 fractions and 4 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, and 22 of radiation. High risk pathology with post-op HPV DNA (+) OR pre-op HPV DNA≤12 copies/mL OR both 5 or more LN+ and ENE+: cisplatin-based radiation with 50 Gy in 25 fractions with 5 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, 22, and 29 of radiation.

    Drug: Cisplatin

Interventions

  • Low risk pathology with post-op HPV DNA (-): cisplatin-based chemoradiation with 30 Gy in 15 fractions and 3 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, and 15 of radiation. Low risk pathology with post-op HPV DNA (+): cisplatin-based chemoradiation with 40 Gy in 20 fractions and 4 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, and 22 of radiation. High risk pathology with post-op HPV DNA (-), excluding patients with both 5 LN+ and ENE+ or pre-op HPV DNA≤12 copies/mL: cisplatin-based radiation with 40 Gy in 20 fractions and 4 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, and 22 of radiation. High risk pathology with post-op HPV DNA (+) OR pre-op HPV DNA≤12 copies/mL OR both 5 or more LN+ and ENE+: cisplatin-based radiation with 50 Gy in 25 fractions with 5 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, 22, and 29 of radiation.

    Also known as: Chemoradiation

06

What researchers measure

Primary outcomes

  1. 2-year progression-free (PFS)

    The primary objective of this study is to assess the 2-year progression-free survival (PFS) of de-intensified post-operative chemoradiation in patients with HPV-associated oropharyngeal cancer when basing treatment intensity on both standard pathologic features and post-operative Blood-based circulating tumor tissue modified viral (cTTMV-HPV DNA)

    Time frame: 2 Years

Secondary outcomes

  1. Overall Survival (OS)

    Proportion of patients alive, based on time from enrollment to death from any cause.

    Time frame: 2 Years

  2. Locoregional Control

    Proportion of patients without local recurrence or regional recurrence, as defined above, based on the time from enrollment to the first evidence of either local or regional recurrence, irrespective of prior distant recurrence. Death from causes unrelated to cancer is a competing event.

    Time frame: 2 Years

  3. Distant Control

    Proportion of patients without distant recurrence, based on time from enrollment to distant recurrence, irrespective of prior local or regional recurrence. Distant metastasis includes any recurrent disease outside of the head and neck, cervical lymph nodes, or retropharyngeal lymph nodes. Death from causes unrelated to cancer is a competing event.

    Time frame: 2 Years

  4. Cause-Specific Survival

    Proportion of patients without oropharyngeal cancer-related or treatment-related death, based on time from enrollment to death from oropharyngeal cancer or treatment. Death from other causes is a competing event.

    Time frame: 2 Years

  5. Mean change in patient-reported outcomes using Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    To assess quality of life changes before, during and after treatment via Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) PRO-CTCAE responses are scored from 0 to 4 (or 0/1 for absent/present), with lower scoring indicating an absence of symptoms to higher scoring reflecting higher severity of symptoms.

    Time frame: 2 Years

  6. Mean change in patient-reported outcomes using Hearing Handicap Inventory for Adults (HHIA-S)

    To assess quality of life changes before, during and after treatment via Hearing Handicap Inventory for Adults (HHIA-S). The scale ranges from 0 to 4 (0 - no, 2 - sometimes, 4- yes) for each question identifying problems with hearing loss, as self-reported by patients. The total number of points for the 25 questions range from 0 to 100, with 0 indicating no handicap to 100 indicating total handicap.

    Time frame: 2 Years

  7. Mean change in patient-reported outcomes using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30)

    To assess quality of life changes before, during and after treatment via EORTC QLQ-C30. The EORTC QLQ-C30 is composed of both multi-item scales and single-item measures. These include 5 functional scales, 3 symptom scales, a global health status / QoL, and 6 single items. All of the scales and single-item measures range in score from 0-100. A high scale score represents a higher response level and represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale represents a high level of problems. Most questions are scored 1 to 4, with exception to global health questions scored from 1 to 7. The raw scores are then standardized by a linear transformation, so that scores range from 0 to 100; a higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms.

    Time frame: 2 Years

  8. Mean change in patient-reported outcomes using the MD Anderson Dysphagia Inventory (MDADI)

    To assess quality of life changes before, during and after treatment via the MD Anderson Dysphagia Index (MDADI). The MDADI is a patient-reported, 20-item scale that quantifies four domains: an individual's global (G), physical (P), emotional (E), and functional (F) perceptions of their swallowing ability. Two summary scores can be obtained from the MDADI: 1) global and 2) composite. The global scale is a single question, scored individually, to assess the overall impact that swallowing abilities have on quality of life. The composite MDADI score summarizes overall performance on remaining 19-items of the MDADI, as a weighted average of the physical, emotional, and functional subscale questions. Summary and subscale MDADI scores are normalized to range from 20 (extremely low functioning) to 100 (high functioning). Five possible responses to the items on the MDADI are: strongly agree, agree, no opinion, disagree, and strongly disagree, and scored on a scale of 1 to 5 respectively.

    Time frame: 2 Years

  9. Mean change in patient-reported outcomes using University of Michigan Xerostomia-Related Quality of Life Scale (XeQoLS)

    To assess quality of life changes before, during and after treatment via the University of Michigan Xerostomia-Related Quality of Life Scale (XeQoLS). XeQOLS is a patient-reported, 15-item scale that measures four domains: physical functioning, pain/discomfort, personal/psychologic functioning, and social functioning. Patient responses to all four domains are averaged, and the total scores range from 0 to 4; an increased xerostomia burden is indicated by a higher score.

    Time frame: 2 Years

  10. Mean change in patient-reported outcomes using 5-level version of the EuroQol five dimensional instrument EQ-5D-5L

    To assess quality of life changes before, during and after treatment via the 5-level version of the EuroQol five dimensional instrument EQ-5D-5L.The EQ-5D-5L descriptive system comprises of five dimensions: (MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN / DISCOMFORT and ANXIETY / DEPRESSION), with each dimension having five response levels: no problems, slight problems, moderate problems, severe problems, unable to /extreme problems - severity level of each dimension are coded from 1 to 5, respectively. The visual analog scale (EQ VAS) attached to this questionnaire records the respondent's overall self-rated perception of current health status on a vertical visual analogue scale, where the endpoints are scored from 0 to 100, 100 being the 'The best health you can imagine' and 0 indicating 'The worst health you can imagine'

    Time frame: 2 Years

  11. Mean change in Dysphagia using MDADI

    To assess dysphagia before, during, and after treatment with the MD Anderson Dysphagia Inventory (MDADI) tool. The MDADI is a patient-reported, 20-item scale that quantifies four domains: an individual's global (G), physical (P), emotional (E), and functional (F) perceptions of their swallowing ability. Two summary scores can be obtained from the MDADI: 1) global and 2) composite. The global scale is a single question, scored individually, to assess the overall impact that swallowing abilities have on quality of life. The composite MDADI score summarizes overall performance on remaining 19-items of the MDADI, as a weighted average of the physical, emotional, and functional subscale questions. Summary and subscale MDADI scores are normalized to range from 20 (extremely low functioning) to 100 (high functioning). Five possible responses to the items on the MDADI are: strongly agree, agree, no opinion, disagree, and strongly disagree, and scored on a scale of 1 to 5 respectively.

    Time frame: 2 Years

  12. Mean change in Dysphagia using Modified Barium Swallow

    To assess dysphagia before, during, and after treatment with the modified barium swallow. MBS is an analysis of swallowing through three phases: oral (mouth), pharyngeal (throat) and upper esophagus. A Modified Barium Swallow Study (MBSS) is a special x-ray that allows the Radiologist (who specializes in using x-rays) and Speech Language Pathologist (SLP) to identify why you are having trouble swallowing. The MBS provides quantitative evaluation of 17 physiologic components of swallowing distributed across three functional domains: oral, pharyngeal, and esophageal. MBS components are scored on an ordinal scale from 0 (indicating no impairment) to a maximum of 2, 3, or 4, depending on the specific component.

    Time frame: 2 Years

  13. 2-year Progression-Free Survival

    To assess the 2-year PFS (Progression-Free Survival) in the high-risk \[extranodal extension (ENE), positive margins, ≥5 positive lymph nodes (LNs)\] and intermediate-risk \[T3, close margins, LN size \> 3cm, 2 or more LN+, lymphovascular invasion (LVI), perineural invasion (PNI)\] subgroups separately. The difference between the proportion of patients alive and without evidence of local, regional, or distant recurrence at 2 years from study enrollment, in high-risk and intermediate subgroups.

    Time frame: 2 Years

07

Study locations

4 of 4 sites recruiting
  • Cedars-Sinai Cancer at Beverly Hills (THO)
    Beverly Hills, California 90211, United States
    Recruiting
    • Clinical Trial Recruitment Navigator · Contact
    • Kevin Scher, MD · Sub investigator
    • David Hoffman, MD · Sub investigator
    • Kamalesh Sankhala, MD · Sub investigator
    • Leland Green, MD · Sub investigator
    • Jeremy Lorber, MD · Sub investigator
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
    Recruiting
    • Zachary S Zumsteg, MD · Contactzachary.zumsteg@cshs.org · 310-423-5842
    • Allen Ho, MD · Sub investigator
    • Jon Mallen-St. Clair, MD · Sub investigator
    • Evan Walgama, MD · Sub investigator
    • Alain Mita, MD · Sub investigator
    • Jun Gong, MD · Sub investigator
    • Ronald Natale, MD · Sub investigator
    • Stephen Shiao, MD · Sub investigator
    • Julie Jang, MD · Sub investigator
    • Zachary S Zumsteg, MD · Principal investigator
  • CS Cancer at Valley Oncology Medical Group
    Tarzana, California 91356, United States
    Recruiting
    • Vanessa Vasco · ContactVanessa.Vasco@cshs.org
    • Benjamin L King, MD · Sub investigator
    • Robert S Reznik, MD · Sub investigator
    • Natasha Banerjee, MD · Sub investigator
    • Johnny K Chang, MD · Sub investigator
    • Ryan Ponec, MD · Sub investigator
    • Anirban Balmanoukian, MD · Sub investigator
  • CS Cancer at the Hunt Cancer Center
    Torrance, California 90505, United States
    Recruiting
    • Sarah Valdez · ContactSarah.Valdez@tmphysicians.com · 310-750-3300
    • Hugo Hool, MD · Sub investigator
    • Vanessa Dickey, MD · Sub investigator
    • David Chan, MD · Sub investigator
    • Syed Jilani, MD · Sub investigator
    • Thomas Lowe, MD · Sub investigator
    • Swati Sikaria, MD · Sub investigator
    • Andrew Horodner, MD · Sub investigator
    • Bryan Chang, MD · Sub investigator
    • Thyra Endicott, MD · Sub investigator
    • Andrew Schumacher, MD · Sub investigator
    • Usama Mahmood, MD · Sub investigator
    • Rebecca Philipson, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jun 2032, 85 months after the start.

Of 63 non-industry phase 2 interventional studies under Oropharyngeal Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 99. This study's planned 85 months is above that.

Counting every sponsor, half of 64 studies reached it within 63 months; a quarter within 49 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2024
First posted
Jun 6, 2024
StartActual
May 12, 2025
Primary completionEst.
Jun 2032
CompletionEst.
Jun 2032
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06445114
Lead sponsor
Zachary Zumsteg
Responsible party
Zachary Zumsteg (Sponsor-Investigator, Cedars-Sinai Medical Center) — Sponsor-investigator
First posted
Jun 6, 2024
Start date
May 12, 2025
Primary completion
Jun 2032 (estimated)
Completion
Jun 2032 (estimated)
Last update
Aug 5, 2026

Study contacts

Clinical Trial Navigator
Contact
GroupCancerTrialInformation@cshs.org
310-423-5842
Zachary S Zumsteg, MD
principal investigator · Cedars-Sinai Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cisplatin

Start the discussion